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Mouse Mesenchymal Stem Cells Suppress 
Antigen-Specifi c TH Cell Immunity Independent 
of Indoleamine 2,3-Dioxygenase 1 (IDO1)
Tobias V. Lanz,1,2 Christiane A. Opitz,1 Peggy P. Ho,3 Ankur Agrawal,3 Christian Lutz,4 Michael Weller,5 
Andrew L. Mellor,6 Lawrence Steinman,3 Wolfgang Wick,1 and Michael Platten1
Due to their immunosuppressive properties, human mesenchymal stem cells (hMSC) represent a promising tool 
for cell-based therapies of autoimmune diseases such as multiple sclerosis (MS). Mouse MSC (mMSC) have been 
used extensively to characterize and optimize route of administration, motility, cellular targets, and immuno-
suppressive mechanisms in mouse models of autoimmune diseases, such as experimental autoimmune enceph-
alomyelitis (EAE). Tryptophan (trp) catabolism by indolamine-2,3-dioxygenase 1 (IDO1) is a chief endogenous 
metabolic pathway that tightly regulates unwanted immune responses through depletion of trp and generation 
of immunosuppressive kynurenines (kyn). IDO1 activity contributes to the immunosuppressive phenotype of 
hMSC. Here, we demonstrate that although IDO1 is inducible in bone marrow-derived mMSC by proinfl amma-
tory stimuli such as interferon-g (IFN-g) and ligands of toll-like receptors (TLR), it does not lead to catabolism 
of trp in vitro. This failure to catabolize trp is not due to defective TLR signaling as demonstrated by induction 
of interleukin 6 (IL-6) by TLR activation. While mMSC suppressed the activation of antigen-specifi c myelin ol-
igodendrocyte glycoprotein (MOG)-reactive T-cell receptor (TCR) transgenic T-helper (TH) cells in co-culture, 
neither pharmacologic inhibition nor genetic ablation of IDO1 reversed this suppressive effect. Finally, systemic 
administration of both, IDO1-profi cient and phenotypically identical IDO1-defi cient mMSC, equally resulted in 
amelioration of EAE. mMSC, unlike hMSC, do not display IDO1-mediated suppression of antigen-specifi c T-cell 
responses.
Introduction
Mesenchymal stem cell (MSC) represent a cellular source for tissue regeneration as they can differentiate 
into multiple cell lineages, such as bone, muscle, cartilage, or 
fat [1]. Due to this ability and their capacity to migrate to and 
to repopulate injured tissues [2], MSC are used in clinical tri-
als to promote muscle and cartilage regeneration. In addition, 
MSC display a potent immunosuppressive phenotype, which 
not only enables them to escape rejection when transplanted 
into allogeneic hosts but also allows them to specifi cally sup-
press the host immune response [3]. This property has not 
only sparked clinical trials demonstrating effi cacy in graft-
versus-host disease (GVHD) but also expanded research to 
explore potential application in other infl ammatory and au-
toimmune diseases. For instance, systemic administration of 
autologous MSC suppresses antigen-specifi c T-cell immunity 
and subsequent central nervous system (CNS) infl ammation 
in experimental autoimmune encephalomyelitis (EAE), a 
mouse model of multiple sclerosis (MS) [4–9]. MSC regulate 
multiple cellular components of the immune system such 
as the maturation and differentiation of antigen-presenting 
cells (APC), the activation of natural killer (NK) cells, and the 
activation and expansion of CD4+ and CD8+ T cells [10–14]. 
The molecular mechanisms of MSC-mediated immunosup-
pression appear to involve cell surface molecules and soluble 
factors [15]. The catabolism of the essential amino acid trp by 
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the inducible enzyme IDO1 is involved in the suppression of 
T-cell immunity by hMSC [16–19]. IDO1-mediated trp catab-
olism is a major immunosuppressive effector pathway that 
inhibits T-cell responses to autoantigens and fetal alloanti-
gens [20,21] and may be instrumental for the therapy of auto-
immune diseases such as MS [7,22–25]. Here, we address the 
role of trp catabolism in the suppression of antigen-specifi c 
T-cell responses by mMSC.
Materials and Methods
Mice
C57Bl/6 and SJL mice were purchased from Charles River 
Laboratories (Sulzfeld, Germany). Transgenic IDO1-defi cient 
(IDO1-/-) mice were generated as previously described [26] 
and were backcrossed on a C57Bl/6 background. 2D2 mice 
on a C57Bl/6 background expressing a T-cell receptor (TCR) 
specifi c for the myelin oligodendrocyte glycoprotein (MOG) 
peptide p35–55 were kindly provided by Vijay Kuchroo [27]. 
The transgenic TCR in heterozygous mice was detected by 
fl ow cytometry of murine blood using antibodies against 
CD4 and Vβ11 (BD Pharmingen, Heidelberg, Germany). All 
animal work was performed in accordance with the German 
animal protection law under the permission of the local au-
thorities in Tübingen and the National Institutes of Health 
guidelines Guide for the Care and Use of Laboratory Animals.
MSC preparation
MSC were isolated from C57Bl/6, IDO1-/-, and SJL mice. 
Femurs and tibiae were removed and cleaned of muscles and 
connective tissue. Epiphyses were cut off and bone marrow 
cells were fl ushed out with D-MEM (HyClone, Logan, UT) 
using a 23-gauge needle. Cells were centrifuged at 1,200 rpm 
and 4°C for 10 min, suspended in Murine MesenCult® Basal 
Medium for Mouse Mesenchymal Stem Cells (Stem Cell 
Technologies, Cologne, Germany) containing 20% Mouse 
Mesenchymal Stem Cell Stimulatory Supplement (Stem Cell 
Technologies), 100 U/mL penicillin, and 100 μg/mL strep-
tomycin (Cambrex, Charles City, IA) (complete Murine 
MesenCult® Medium), plated in 75-cm2 fl asks (Corning, 
Corning, NY) at a concentration of 5 × 105/mL and incu-
bated at 37°C and 5% CO2. Medium was changed after 7 days 
and the adherent cell fraction expanded in complete Murine 
MesenCult® Medium. MSC were characterized by fl ow cy-
tometry using a DAKO Cytomation CyanADP Analyzer 
(DAKO Cytomation, Hamburg, Germany) and DAKO 
Summit software. The following antibodies were used for 
FACS analysis: anti-CD11b, anti-CD34, anti-CD44, anti-CD45 
(ebioscience, San Diego, CA), anti-CD9 (BD Pharmingen), 
anti-CD29 (Biolegend, San Diego, CA), anti-CD90 (Cedarlane, 
Burlington, ONT, Canada), and corresponding isotype con-
trols (ebioscience). Osteogenic differentiation was performed 
as described [28] with minor variations. In brief, osteogenic 
differentiation was induced by adding 0.1 mM dexameth-
asone, 0.05 mM ascorbic acid, and 10 mM glycerol 2-phos-
phate disodium salt hydrate (Sigma, Munich, Germany) to 
complete D-MEM, containing 10 % fetal calf serum (FCS; 
Biochrom, Berlin, Germany), and 100 U/mL penicillin and 
100 μg/mL streptomycin (PAA Laboratories, Pasching, 
Austria). Cells were plated in this medium in 94-mm tis-
sue culture dishes (Cellstar/Brightpoint, Trier, Germany). 
Control cells were seeded in complete D-MEM without fur-
ther supplements. After 6 weeks of culture, calcium deposits 
were detected by Alizarin Red S (Sigma) staining.
Dendritic cell (DC) preparation
Dendritic cell (DC) were generated from C57Bl/6 and SJL 
mice. Bone marrow cells were isolated as described above. 
Cells were suspended in RPMI 1640 (Cambrex), supple-
mented with 10% FCS (Biochrom), 100 U/mL penicillin, 
and 100 μg/mL streptomycin (Cambrex; complete RPMI), 
and 20 ng/mL (106 U/mL) recombinant murine Granulocyte 
Macrophage Colony-Stimulating Factor (rm-GM-CSF) 
(Immunotools, Friesoythe, Germany). The 107 bone marrow 
cells were seeded in 75-cm2 fl asks (Corning). On day 2, 10 
mL of complete RPMI, containing 40 ng/mL rm-GM-CSF, 
was added. On day 4, cells were washed twice with PBS and 
detached by incubating cells with 3 mL of accutase for 15 
min at 37°C. Cells were centrifuged at 1,200 rpm and 4°C for 
10 min, then resuspended in complete RPMI containing 20 
ng/mL rm-GM-CSF at 5 × 105 cells/mL and seeded in 6-well 
plates with 3 mL/well. On day 6, 3 mL of complete RPMI, 
supplemented with 40 ng/mL rm-GM-CSF, was added. On 
day 7, we obtained immature DC, ready to be matured via 
cytokines or TLR ligands.
T-cell proliferation assay
For T-cell proliferation assays, spleens were removed 
and dissociated through a 40-μm cell strainer (BD Falcon, 
Heidelberg, Germany) to singularize splenocytes and to re-
move connective tissue, then washed with PBS and centri-
fuged at 1,200 rpm and 4°C for 10 min. Lysis of erythrocytes 
was performed by suspending the pelleted splenocytes in 
ACK Lysing Buffer (Cambrex) for 1 min. Cells were washed 
twice with PBS and resuspended in complete RPMI. For T-cell 
proliferation assays, splenocytes were seeded in 96-well 
plates (5 × 105 cells/well) on 0–5,000 mMSCs from C57Bl/6 
or IDO-/- mice seeded 2 days before. Before 24 h, mMSCs had 
been pretreated with 50 μg/mL polyinosinic:polycytidylic 
acid (pI:C; Sigma), 5 μg/mL lipopolysaccharide (LPS, from 
Salmonella typhii; Sigma), or 500 IU/mL IFN-γ (Immunotools). 
Then mMSC were washed 3 times with PBS to remove all 
remnants of pI:C, LPS, and IFN-γ. Immediately, splenocytes 
(5 × 105 cells/well) of 2D2 mice were added. Activation of 
T cells was achieved by adding 10 μg/mL MOG p35–55 
(MEVGWYRSPFSRVVHLYRNGK, Stanford Protein and 
Nucleic Acid Biotechnology Facility, Stanford, CA). In some 
experiments, 1 mM 1-methyl-l-tryptophan (1-l-MT; Sigma) 
was added immediately after addition of splenocytes. Before 
harvesting, cultures were pulsed with 3H-methylthymidine 
(Amersham-Pharmacia Biotech, Munich, Germany) for the 
last 18 h. Then the 96-well plates were freeze–thawed for 
3 times and harvested using a Tritium Harvester (Tomtec, 
Unterschleißheim, Germany) and a b-plate reader (Wallac, 
Monza, Italy) with BetaWin software. The counts of mMSC 
proliferation without splenocytes were subtracted from the 
counts of the co-cultures.
qRT-PCR
RNA was isolated using the Qiagen RNAeasy RNA 
isolation kit (Qiagen, Hilden, Germany) according to 
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manufacturer’s instructions. cDNA was synthesized with 
the SuperscriptTM Choice System (Invitrogen, Carlsbad, CA) 
using random hexamers. qRT-PCR was performed in 3 serial 
dilutions, each in duplicates using an ABI 7000 thermal cy-
cler with SYBR Green PCR Mastermix (Eurogentec, Cologne, 
Germany). Data were evaluated with AB 7000 System SDS 
software. PCRs were checked by including controls without 
prior reverse transcription and by both melting curve and 
gel analysis. Relative quantifi cation of gene expression was 
determined by comparison of threshold values. All results 
were normalized to b-actin. Primers were designed across 
exon boundaries. The sequences of the primers were the 
following: TLR1: fwd: TCAAGCATTTGGACCTCTCCT, 
rev: TTGTACCCGAGAACCGCTCA; TLR2: fwd: CCAGA
CACTGGGGGTAACATC, rev: CGGATCGACTTTAGAC
TTTGGG; TLR3: fwd: GGGGTCCAACTGGAGAACCT, rev: 
CCGGCGAGAACTCTTTAAGTGG; TLR4: fwd: ATGGC
ATGGCTTACACCACC, rev: GAGGCCAATTTTGTCTCC
ACA; TLR5: fwd: TCAGACGGCAGGATAGCCTTT, rev: 
AATGGTCAAGTTAGCATACTGGG; TLR6: fwd: GACTCT
CCCACAACAGGATACG, rev: TCAGGTTGCCAAATTCCTT
ACAC; TLR7: fwd: TCTTACCCTTACCATCAACCACA, rev: 
CCCCAGTAGAACAGGTACACA; TLR8: fwd: CAAACAA
CAGCACCCAAATGAA, rev: AGGCAACCCAGCAGG
TATAGT; TLR9: fwd: ACTCCGACTTCGTCCACCT, rev: 
GGCTCAATGGTCATGTGGCA; b-actin: fwd: TGTCCC
TGTATGCCTCTGGT, rev: CACGCACGATTTCCCTCTC; 
IDO1: fwd: GCTTTGCTCTACCACATCCAC, rev: CAGG
CGCTGTAACCTGTGT; KYNA: fwd: AGTGGGCTGCAC
TTTTATACTG, rev: TGCAAACAGGTTGCCTTTCAG; KMO: 
fwd: TGATGTGTACGAAGCTAGGGA, rev: TCATGGGCA
CACCTTTGGAAA; 3-HAAO: fwd: GGAGGCCCCAATACC
AGGA, rev: TATAGGCACGTCCCGGTGTT.
Cytokine ELISA
Supernatants of mMSC for cytokine ELISA were gener-
ated by plating 5 × 104 cells in 24-well plates (BD Falcon) in 
1 mL of complete RPMI. After 24 h, cells were stimulated 
with 50 μg/mL pI:C, 5 μg/mL LPS, or 500 IU/mL IFN-γ. 
Supernatants were collected after 24 and 72 h. ELISA for in-
terleukin 2 (IL-2), IL-4, IL-6, IL-10, IL-12p40, IL-17A, IFN-γ, 
and tumor necrosis factor (TNF; ebioscience) were per-
formed according to manufacturer’s instructions.
Annexin–PI fl ow cytometry analysis
For Annexin- and propidium iodide (PI) staining, cells 
were seeded in 6-well plates at a concentration of 105/well 
in complete RPMI. After 24 h, cells were treated with 50 μg/
mL pI:C or 5 μg/mL LPS for 24 h. Cells were detached using 
accutase, washed twice with PBS, and stained with Annexin 
V-FITC (BD Pharmingen) and PI (Sigma) for 15 min. Flow cy-
tometry was performed using a Cyan ADP Analyzer (DAKO 
Cytomation) and DAKO Summit software.
HPLC analysis of tryptophan metabolites
Supernatants of mMSC were obtained as described above. 
HPLC analysis was performed according to Hervé et al. [29] 
using a Beckman HPLC with PDA detection and Lichrosorb 
RP-18 column (250 mm × 4 mm ID, 5 μm). Kyn release and 
tryptophan degradation were measured in complete RPMI 
1640 media (Cambrex). The medium was harvested from 
24-well plates at the indicated time points, centrifuged, and 
frozen until further analysis. After thawing, the samples 
were supplemented with trichloroacetic acid for protein pre-
cipitation, centrifuged, and 100 μL of the supernatant was 
analyzed by HPLC. Standard curves were generated with 
l-kyn and l-trp (Sigma) in the same medium. Since FCS con-
tains kyn, low kyn concentrations (~1 μM) were detected in 
all samples and medium without cells was always measured 
for comparison.
Induction and treatment of EAE
Female C57Bl/6 mice were immunized subcutane-
ously (s.c.) with 100 μg/mouse MOG p35–55 in incomplete 
Freund’s Adjuvants (Difco, Detroit, MI) containing 200 μg 
Mycobacterium tuberculosis (Difco) per mouse. Concomitantly, 
200 ng/mouse pertussis toxin diluted in 100 μL of PBS was 
injected i.v., which was repeated 2 days later. Clinical signs 
of disease were scored daily according to a standard scor-
ing system, representing 0 = no clinical signs, 1 = loss of 
tail tone, 2 = hind limb weakness, 3 = complete hind limb 
paralysis, 4 = hind limb and forelimb paralysis, 5 = mor-
ibund or dead. On days 4 and 9 after immunization, mice 
were injected intraperitoneally (i.p.) with 106 mMSC from 
C57Bl/6 or IDO1-/- mice, diluted in 200 μL of PBS. Control 
mice received equal volumes of PBS without cells.
Statistical analyses
Results were assessed by applying Student’s t-test sta-
tistics to the experimental data obtained in vitro. In vivo 
data were statistically evaluated using the Mann–Whitney 
U-test.
Results
Characterization of mMSC
MSC were isolated from wild-type C57Bl/6, IDO-/- 
C57Bl/6 and SJL/J mice. Flow cytometry demonstrated that 
the cells were CD9+, CD29+, CD44+, CD90+, CD11b-, CD34-, 
CD45-, which is indicative of an MSC phenotype (Fig. 1A). 
Staining of calcium deposits verifi ed the capacity to differ-
entiate along the osteogenic lineage (Fig. 1B).
Tryptophan catabolism in mMSC
Trp catabolism was analyzed in mMSC. To this end, 
mMSC were stimulated with IFN-g or the TLR ligands 
pI:C or LPS. Then, mRNA expression of IDO1, the main 
inducible trp catabolizing enzyme, and the enzymes in its 
downstream pathway, kynureninase (KYNA), kynurenine 
monooxygenase (KMO), and 3-hydroxyanthranilic acid ox-
idase (3-HAAO) (Fig. 2) was determined. Naïve mouse DC 
served as a positive control. As opposed to mDC, there was 
no constitutive IDO1 mRNA expression in mMSC. While 
IFN-g induced a strong up-regulation in both mMSC and 
mDC, induction of IDO1 mRNA by TLR ligands was weak 
in mMSC (Fig. 3A).
HPLC analysis of trp demonstrated that the increase of 
IDO1 mRNA in mMSC by TLR ligation or IFN-g stimulation 
did not result in IDO1 enzyme activity despite induction 
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of IDO1 mRNA (Fig. 3B). Interestingly, kyn in the cell cul-
ture media decreased after TLR ligation (Fig. 3C), possibly 
indicating immediate catabolization via the downstream 
enzymes. We thus analyzed the expression of downstream 
kyn-catabolizing enzymes. KYNA was constitutively 
expressed in mDC and—albeit at lower levels—mMSC, 
but unlike in mDC it was not down-regulated in mMSC by 
TLR ligands or IFN-g (Fig. 3D). IFN-γ or TLR stimulation 
resulted in down-regulation of mRNA expression of KMO 
and 3-HAAO only in mDC, while mRNA of those 2 enzymes 
was not detected in mMSC (Fig. 3E and 3F). Interestingly, 
when mMSC were stimulated with pI:C or LPS, HPLC 
analysis detected an additional peak that does not appear 
after stimulation with IFN-g but can be increased by com-
bination of TLR ligand and IFN-g. This additional peak cor-
related reciprocally with the peak size of kyn, suggesting it 
may be a derivative of it (Fig. 3G). This peak is not identical 
with trp and all its tested metabolites: kynurenic acid, 3-hy-
droxykynurenine, anthranilic acid, 3-hydroxyanthranilic 
acid, picolinic acid, quinolinic acid, kynuramic acid, or nic-
otinic acid.
mMSC express functional TLR
The reduced responsiveness of mMSC to TLR activation 
is in sharp contrast to hMSC, which display strong IDO1 ac-
tivity in response to TLR ligation [19]. To see whether this 
FIG. 1. Characterization of mouse mesenchymal stem cells (mMSC). (A) Flow cytometric analysis of the MSC-determining sur-
face markers CD9, CD29, CD44, CD90, CD11b, CD34, and CD45 on mMSC derived from C57Bl/6 bone marrow. (B) Osteogenically 
differentiated C57Bl/6 MSC stained for calcium deposits with Alizarin Red S. Left panel: macroscopic aspect of osteogenically 
differentiated cells and undifferentiated control cells. Middle and right panel: 10× magnifi cation. Flow cytometric analyses are 
representative for at least 2 independent measurements. Color images available online at www.liebertonline.com/scd.
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FIG. 2. Catabolic pathway of tryptophan (modifi ed from 
Ref. [25]).
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mMSC suppress myelin-specifi c T cells
As an in vitro model for antigen-specifi c T-cell immunity, 
we chose myelin-specifi c T cells from 2D2 mice with a trans-
genic TCR specifi c for the immunodominant peptide p35–55 
of MOG expressed on CD4+ T cells. MOG p35–55-specifi c 
IFN-g-secreting TH1-polarized T cells can be induced to be-
come encephalitogenic in EAE [27]. IFN-g, in turn, induces 
IDO1 expression in mMSC (Fig. 3A). To evaluate whether 
mMSC suppress the proliferation of MOG-specifi c CD4+ T 
cells, splenocytes from 2D2 mice were activated with MOG 
p35–55 in the presence of syngeneic mMSC. Figure 5A shows 
that mMSC suppress the proliferation of MOG-specifi c 
CD4+ T cells in a concentration-dependent manner. Adding 
1-l-MT, a competitive IDO1 inhibitor [19], to the mMSC/
splenocyte culture did not restrict the capacity of mMSC to 
suppress T-cell proliferation indicating that mMSC-derived 
IDO1 is not involved in the suppression of T-cell proliferation 
(Fig. 5B). Of note, in the absence of mMSC, 1-l-MT led to a 
25% reduction of T-cell proliferation indicating that 1-l-MT 
may interfere with our system independently of IDO1 
reduced responsiveness refl ects impaired functionality of 
TLR in mMSC, we fi rst analyzed TLR mRNA expression. 
Figure 4A shows that both mDC and mMSC, isolated from 
C57Bl/6 mice, express TLR1–9. Expression levels of mDC 
and mMSC were comparable except for TLR7, TLR8, and 
TLR9, which were expressed at orders of magnitude lower in 
mMSC compared to mDC. TLR3 and TLR4, the receptors for 
pI:C and LPS, respectively, were highly expressed in mMSC. 
mMSC from SJL/J mice showed similar fl ow cytometric pro-
fi le and similar TLR expression patterns as C57Bl/6 mMSC 
(Fig. 4B and 4C). To analyze the functionality of TLR3 and 
TLR4 in mMSC, we determined the mRNA expression and 
release of various cytokines in response to activation with 
pI:C and LPS. Both pI:C and to a lesser extent LPS induced 
the release of IL-6 in mMSC and mDC (Fig. 4D and 4E), in-
dicating that the lack of relevant induction of trp catabolism 
by TLR ligands in mMSC is not due to lack of functional TLR 
signaling. There was no change in the production of the other 
tested cytokines: IL-10, IL-12, IL-23, IFN-γ, and TNF (Table 1). 
IL-2, IL-4, and IL-17 were not detected (data not shown). Of 
note, TLR activation did not result in mMSC death (Fig. 4F).
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FIG. 3. Effects of TLR ligands and IFN-γ on tryptophan-catabolizing enzymes. (A) Relative expression of indolamine-2,3-
dioxygenase 1 (IDO1) mRNA in C57Bl/6 DC and C57Bl/6 mesenchymal stem cell (MSC) after stimulation with TLR ligands or 
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of trp (B) and kyn (C) in the cell culture supernatant of C57Bl/6 MSC after stimulation with TLR ligands or IFN-γ, measured by 
HPLC. (D) Relative expression of KYNA mRNA in C57Bl/6 DC and C57Bl/6 MSC after stimulation with TLR ligands or IFN-γ, 
measured by qRT-PCR. Values are given as transcript abundance relatively to b-actin expression. (E, F) Relative expression of 
KMO (E) and 3-HAAO (F) mRNA in C57Bl/6 DC after stimulation with TLR ligands or IFN-γ, measured by qRT-PCR. Values 
are given as transcript abundance relatively to b-actin expression. (G) HPLC analysis of kyn and the unknown trp metabolite 
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data represent mean + standard error of the mean (SEM) of at least 2 independent experiments, each in duplicates and 3 serial 
dilutions. HPLC data are mean ± SEM of at least 4 independent experiments. *P < 0.05; **P < 0.01 (Student’s t-test).
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FIG. 4. TLR expression on mouse 
mesenchymal stem cells (mMSC). (A) 
Relative TLR1–9 mRNA expression in 
C57Bl/6 DC or C57Bl/6 mesenchymal 
stem cell (MSC), measured by qRT-
PCR. Values are given as transcript 
abundance relatively to b-actin ex-
pression. (B) Flow cytometric analysis 
of MSC-determining surface markers 
on MSC derived from bone marrow 
of SJL/J mice. (C) Relative TLR1–9 
mRNA expression in SJL/J DC and 
SJL/J MSC, measured by qRT-PCR. 
Values are given as transcript abun-
dance relatively to b-actin expression. 
(D) Relative IL-6 mRNA expression 
in C57Bl/6 DC and C57Bl/6 MSC 
after stimulation with TLR ligands or 
IFN-γ, measured by qRT-PCR. Values 
are given as transcript abundance 
relatively to b-actin expression. (E) 
IL-6 production measured by ELISA 
in supernatants of C57Bl/6 DC and 
C57Bl/6 MSC after stimulation with 
TLR ligands or IFN-γ. (F) C57Bl/6 
MSC cell death analysis by FACS 
analysis of Annexin V and PI after 
stimulation with TLR ligands. qRT-
PCR data are mean + standard error 
of the mean (SEM) from 3 indepen-
dent experiments, each performed 
in duplicates and 3 serial dilutions. 
*P < 0.05; **P < 0.005 (Student’s t-test). 
Flow cytometric analyses are repre-
sentative data for at least 2 indepen-
dent measurements. ELISA data are 
representative values from 1 of 2 inde-
pendent experiments.
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IDO1 is not involved in mMSC-mediated 
immunosuppression in EAE
We next analyzed the role of mMSC trp catabolism in vivo 
by immunizing C57Bl/6 mice with MOG p35–55 to induce EAE. 
Systemic administration of mMSC led to an attenuation of dis-
ease severity as determined by the grade of paralysis. IDO-/- 
mMSC were equally effective in reducing disease severity as 
wild-type mMSC (Fig. 7A). We then used lymph node cells of 
immunized animals of all 3 groups and restimulated them in 
vitro with MOG p35–55. Lymphocytes from animals treated 
with wild-type or IDO1-/- mMSC showed reduced proliferation 
compared to lymphocytes from the control group. There was 
no difference between wild-type- and IDO1-/- mMSC-treated 
groups (Fig. 7B). While the production of the T-cell cytokines 
IL-2, IL-4, IL-6, IL-10, and IL-12/23p40 remained unchanged, 
treatment with both wild-type and IDO1-/- mMSC led to an 
equal reduction of IL-17 release from lymph node cells after re-
stimulation with MOG p35–55 ex vivo. Interestingly TNF and 
IFN-γ seemed to be even more suppressed by IDO-/- mMSC 
than by the wild-type mMSC (Fig. 7C).
activity. Moreover, pretreatment of mMSC with IFN-g to 
induce IDO1 did not increase the immunosuppressive ca-
pacities of mMSC (Fig. 5C). Also, stimulation of mMSC with 
pI:C and LPS did not have any effect on T-cell proliferation 
(Fig. 5D).
IDO1 is not involved in mMSC-mediated 
immunosuppression in vitro
To further substantiate the fi nding that IDO1 is not in-
volved in mMSC-mediated inhibition of MOG-specifi c 
T cells, we used mMSC from IDO1-defi cient mice. IDO1-/- 
mMSC did not differ substantially from wild-type C57Bl/6 
mMSC with respect to phenotype, differentiation capacity, 
and TLR expression (Fig. 6A–6D). IL-6 induction in response 
to LPS, however, was lower in IDO-/- MSC than wild-type 
MSC (Fig. 6D). When incubated with 2D2 splenocytes acti-
vated with MOG p35–55, IDO1-/- mMSC displayed similar 
immunosuppressive activity as their wild-type counter-
parts, indicating that IDO1 is not involved in mMSC-medi-
ated modulation of TH cell activation (Fig. 6E).
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FIG.  5. Indolamine-2,3-dioxy-
ge nase 1 (IDO1)-independent 
immunosuppression by mouse 
mesenchymal stem cell (mMSCs). 
(A–D) Proliferation of myelin oli-
godendrocyte glycoprotein (MOG) 
p35–55 activated 2D2 splenocytes 
in co-culture with C57Bl/6 MSC at 
various ratios, quantifi ed by 3H-thy-
midine incorporation. (B) 1-l-MT or 
vehicle control was added during 
the stimulation with peptide. (C, 
D) mMSC were preactivated with 
IFN-g (C), pI:C, or LPS (D). Data in 
(A) show mean + standard error 
of the mean (SEM) of triplicates of 
1 representative experiment out of 
10, data in (B–D) represent mean + 
SEM of 3 independent T-cell pro-
liferation assays. All experiments 
were carried out in triplicates and 
measured by 3H-thymidine uptake. 
*P < 0.05 (Student’s t-test).
Table 1. IDO1–/– and Wild-Type mMSC Express Functional TLR
Unstimulated pI:C LPS IFN-γ
 wt DC wt MSC –/– MSC wt DC wt MSC –/– MSC wt DC wt MSC –/– MSC wt DC wt MSC –/– MSC
IL-6 27  9  1 823 566 455 839 355 128 40  1  2
IL-10 52 41 53  41  83 101  52 65  73 59 47 50
IL-12  7 10 18  73  12  23 210 14  17  3 13 34
IFN-γ  3  1  1  9  14  20  1 3  1 n/a n/a n/a
TNF 11  9 11  24  19  8  16 15  1 10 10 13
Production of IL-6, IL-10, IL-12/23p40, IFN-γ, and TNF measured by ELISA in cultured DC, and IDO-/- MSC or wild-type 
MSC. Values are given as mean pg/mL from duplicates. Data are representative of 2 independent experiments.
Abbreviations: n/a: not applicable; MSC: mesenchymal stem cell.
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Discussion
MSC have the unique ability to suppress multiple cel-
lular components of the immune system. The clinical devel-
opment of hMSC as a source for tissue regeneration and as 
vehicles to deliver immunosuppressive signals to infl amed 
tissues after systemic administration has made rapid pro-
gress in the past several years. A recent phase II clinical trial 
has shown effi cacy of systemic treatment of patients with 
steroid-resistant acute graft-versus-host disease with allo-
geneic bone marrow-derived hMSC [30]. Potential clinical 
applications have been extended to autoimmune diseases 
such as MS and rheumatoid arthritis, where preclinical 
mouse models have demonstrated the effi cacy of autologous 
bone marrow-derived MSC [15]. The mechanism of immu-
nosuppressive action of MSC has not been fully elucidated 
FIG.  6. Indolamine-2,3-dioxygenase 
1 (IDO1) is dispensable for mouse mes-
enchymal stem cells (mMSCs)-mediated 
immunosuppression in vitro. (A) Flow 
cytometry analysis of mesenchymal stem 
cells (MSCs)-determining surface mark-
ers on MSC derived from bone marrow 
of IDO1-/- mice. (B) Osteogenically dif-
ferentiated IDO-/- mMSC stained for cal-
cium deposits with Alizarin Red S. Left 
panel: macroscopic aspect of osteogeni-
cally differentiated cells and undiffer-
entiated control cells. Middle and right 
panel: 10× magnifi cation. (C) Relative 
TLR1–9 mRNA expression in C57Bl/6 
DC and IDO-/- MSC, measured by qRT-
PCR. Values are given as transcript 
abundance relatively to b-actin expres-
sion. (D) IL-6 production measured by 
ELISA in supernatants from C57Bl/6 DC 
and IDO1-/- MSC after stimulation with 
TLR ligands or IFN-γ. (E) Proliferation 
of 2D2 splenocytes in co-culture with 
wild-type C57Bl/6 MSC or IDO1-/- MSC 
in different ratios, quantifi ed by 3H-thy-
midine incorporation. Flow cytometry 
analyses are representative for 2 inde-
pendent measurements. qRT-PCR data 
are mean + standard error of the mean 
(SEM) from 3 independent experiments, 
each performed in duplicates and 3 se-
rial dilutions, respectively. ELISA data 
are representative values from 1 of 2 
independent experiments. Proliferation 
data represent mean + SEM of 3 inde-
pendent T-cell proliferation assays, each 
carried out in triplicates and measured 
by 3H-thymidine uptake. Color images 
available online at www.liebertonline.
com/scd.
but appears to involve membrane-bound and soluble fac-
tors. Among the soluble factors, the oxidative catabolism of 
trp along the kyn pathway is an important immunosup-
pressive mechanism restricting antigen-specifi c T-cell 
responses in autoimmunity [24]. This pathway is operative in 
hMSC and delivers immunosuppressive signals to T cells, 
although it is dispensable when signaling through the 
IFN-g receptor is lacking [17]. We have recently shown that 
TLR ligands activate immunosuppressive trp catabolism via 
IDO1 in hMSC and that inhibition of IDO1 reverses hMSC-
mediated T-cell paralysis [19]. This study was initiated to 
examine the contribution of IDO1-mediated immunosup-
pression to the therapeutic effi cacy of mMSC in a mouse 
model of MS.
Using a transgenic mouse model with CD4+ T cells carry-
ing a TCR specifi c for an immunodominant epitope of MOG, 
CD9
A
C
D E
CD11b
C
el
l C
ou
nt
s
TLR1 TLR2 TLR3 TLR4 TLR5 TLR6 TLR7 TLR8 TLR9
Fluorescence Intensity
C57BI/6 DC
C57BI/6 DC
Unstim. 0 MSC
MSC:Splenocytes
1:10.000 1:100
IL
-6
 [p
g/
m
L]
pl:C LPS IFN-γ
600 140
120
100
80
60
40
20
0
500
400
300
200
100
0
R
el
at
iv
e 
T
LR
 E
xp
re
ss
io
n
IDO-/- MSC
IDO-/- MSC C57BI/6 MSC IDO-/- MSC
B Osteo Osteo
10x 10x
Control Control
CD34 CD45
Isotype Controls
Antibody Staining
CD29 CD44 CD90
624 568 586 577
432
288
144
0
439
293
146
0
426
284
142
0
468
312
C
ou
nt
s
C
ou
nt
s
C
ou
nt
s
C
ou
nt
s
C
ou
nt
s
C
ou
nt
s
C
ou
nt
s
567
100
10–1
10–2
10–3
10–4
10–5
10–6
10–7
520 528
396
264
132
0
390
280
130
0
425
283
141
0
156
0
100 101 102
FL2 Log FL2 Log
103 104
100 10
1
102
FL8 Log
103 104 10
0 101 102
FL8 Log
103 104 10
0 101 102
FL8 Log
103 104
100 101 102 103 104
FL1 Log
100 101 102 103 104
FL8 Log
100 101 102 103 104
[3
H
]T
hy
m
id
in
e 
In
co
rp
or
at
io
n
[c
pm
 ×
 1
00
0]
IDO1-INDEPENDENT IMMUNOSUPPRESSION BY MOUSE MSC 665
16 25 
20 
15 
10 
5 
0 
0 2.5 5 10 20 0 2.5 5 10 20 
IL-2 
14 
12 
10 
8 
6 
4 
2 
0 
300 400 1000 
800 
600 
400 
200 
0 
0 2.5 5 10 20 
300 
200 
100 
12000 600 
500 
400 
300 
200 
100 
0 
* 
10000 
8000 
6000 
4000 
2000 
0 
0 
0 2.5 5 10 20 
250 
200 
150 
100 
50 
1750 
1500 
1250 
1000 
750 
500 
250 
0 
0 
0 2.5 5 20 10 
0 2.5 5 20 10 
* 
* 
0 2.5 5 20 10 0 2.5 5 20 10 
MOG p35-55 [ug/mL] 
MOG p35-55 [ug/mL] 
IL-6 
IL-17 IFN-γ TNF 
IL-12p40 IL-10 
IL-4 
IL
-6
 [u
g/
m
L]
 
IL
-1
7 
[u
g/
m
L]
 
IL
-1
0 
[u
g/
m
L]
 
IF
N
-γ
 [u
g/
m
L]
 
T
N
F
 [u
g/
m
L]
 
IL
-1
2p
40
 [u
g/
m
L]
 
[3
H
] T
hy
m
id
in
e 
In
co
rp
or
at
io
n 
[c
pm
 ×
 1
00
0]
 
0 
MOG p35-55 [ug/mL] MOG p35-55 [ug/mL] 
MOG p35-55 [ug/mL] 
MOG p35-55 [ug/mL] MOG p35-55 [ug/mL] 
MOG p35-55 [ug/mL] 
MOG p35-55 [ug/mL] 
IL
-2
 [u
g/
m
L]
 
IL
-4
 [u
g/
m
L]
 
10 20 
M
ea
n 
C
lin
ic
al
 S
co
re
 
Vehicle Control 
Days 
Vehicle Control 
* 
* 
* 
* 
C57BI/6 MSC C57BI/6 MSC 
IDO-/- MSC 
IDO-/- MSC 
Vehicle Control 
4 
3 
2 
1 
0 
1 2 3 
Injections of MSC 
4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 
C57BI/6 MSC IDO-/- MSC 
120 
100 
80 
60 
40 
20 
0 
* 
* * * 
* * * 
A 
B C 
FIG. 7. Indolamine-2,3-dioxygenase 1 (IDO1) is dispensable for mouse mesenchymal stem cells (mMSCs)-mediated immu-
nosuppression in vivo. (A) EAE disease scores followed up for 28 days. Animals were treated with 2 i.p. injections of vehicle 
control, wild-type C57Bl/6 mesenchymal stem cells (MSCs), or IDO-/- MSC on days 4 and 9 after immunization, means ± 
SEM are shown, n = 10 mice per group, *P < 0.05 between wild-type MSC-treated group and controls, °P < 0.05 between 
IDO-/- MSC-treated group and controls according to Mann–Whitney U-test. (B) Proliferation of myelin oligodendrocyte gly-
coprotein (MOG) p35–55-restimulated lymphocytes from EAE mice treated with vehicle control, wild-type C57Bl/6 MSC, or 
IDO1-/- MSC. (C) Production of IL-2, IL-4, IL-6, IL-10, IL-12/23p40, IL-17, IFN-γ, and TNF measured by ELISA in MOG p35–55 
restimulated lymphocyte cultures of mice treated with vehicle control, wild-type C57Bl/6 MSC, or IDO1-/- MSC. Cells were 
pooled from 10 mice per group and assays were carried out in triplicates, means ± standard error of the mean (SEM) are 
shown, *P < 0.05 between wild-type C57Bl/6 MSC-treated group and controls, °P < 0.05 between IDO-/- MSC-treated group 
and controls (Student’s t-test).
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we show that autologous bone marrow-derived mMSC sup-
press proliferation of MOG-specifi c T cells (Fig. 5A) sup-
porting the notion that suppression of encephalitogenic 
myelin-specifi c T cells is involved in the therapeutic effi cacy 
of MSC in EAE [4].
We show, however, that as opposed to human MSC, 
mouse MSC cannot be activated to express functional IDO1 
activity by stimulation with TLR ligands or with IFN-g. 
This inability to catabolize trp is likely to be species- and 
not strain-dependent, since neither C57Bl/6 MSC (Fig. 3B) 
nor phenotypically similar SJL/J MSC (Fig. 4B and 4C) dis-
played IDO1 enzyme activity (data not shown). This fi nd-
ing is in line with in vitro data from previous studies that 
failed to detect IFN-g-inducible IDO1 enzyme activity in 
murine MSC cell lines [31,32]. Interestingly, IFN-g induced 
a strong IDO1 mRNA expression comparable to DC (Fig. 2)
[TS: In artwork, Please Strike out A in Figure 2], pointing 
to post-transcriptional or post-translational mechanisms 
regulating IDO1 enzyme activity. An identical discrepancy 
between IDO1 mRNA expression and enzyme activity has 
been observed in CD8a+ DC [33]. The mechanisms involved 
in post-transcriptional and post-translational regulation of 
IDO1 enzyme activity remain elusive but may involve nitra-
tion of the enzyme by peroxynitrite [34].
As we and others measured IDO1 activity by determining 
the concentration of kyn in the cell culture supernatant via 
HPLC, it was conceivable that kyn produced from trp after 
IFN-g stimulation is catabolized further to downstream 
metabolites such as 3-hydroxykynurenine and 3-hydroxyan-
thranilic acid. The fact that trp levels in the supernatant of 
IFN-g-stimulated mMSC did not decrease and that the kyn-
catabolizing enzymes are down-regulated rather than up-
regulated renders this hypothesis unlikely. Interestingly, 
stimulation with TLR ligands resulted in catabolism of kyn 
present in the cell culture media as evidenced by a reduction 
of kyn and simultaneous accumulation of a kyn catabolite in 
the supernatant (Fig. 3C and 3G). The kyn catabolite is un-
likely due to activity of the kynurenine catabolizing enzyme 
KYNA as this enzyme is suppressed rather than induced by 
pI:C or LPS. KMO and 3-HAAO are not expressed by mMSC 
(Fig. 3D–3F). Moreover, the unidentifi ed kyn catabolite (Fig. 
3G) is not one of the classic catabolites such as kynurenic 
acid, 3-hydroxykynurenine, anthranilic acid, 3-hydroxyan-
thranilic acid, picolinic acid, quinolinic acid, kynuramic 
acid, or nicotinic acid as evidenced by HPLC analysis (data 
not shown). We are currently investigating the identity of 
this kyn catabolite.
The failure of the TLR ligands pI:C and LPS to induce 
functional trp catabolism led us to investigate whether TLR 
signaling in general is operational in bone marrow-derived 
mMSC. We show that mMSC express TLR1–9 mRNA at levels 
comparable to mDC, except for TLR7, TLR8, and TLR9 whose 
expression levels are 3 orders of magnitude lower than in 
mDC (Figs. 4A, 4C, and 6C). These results are in line with 
another study in mMSC [35]. As in human MSC [19], TLR3 
and TLR4 are expressed at levels comparable to DC (Figs. 
4A, 4C, and 6C). We show that the TLR pathway is not dys-
functional per se (Figs. 4D, 4E, 6D) indicating that—unlike 
in hMSC—activation of the TLR pathway alone is not suffi -
cient to activate functional IDO1 in mMSC. It is tempting to 
speculate that IDO competence in mice is per se restricted to 
hematopoietic cells. Jasperson and colleagues have recently 
shown that IDO1-competent APC suppress GVHD, while 
IDO1 expression in epithelial cells was dispensable [36].
Our results identify an important immunological dif-
ference between human and murine MSC. In this respect, 
mMSC are similar to hDC where TLR activation requires a 
second signal to induce IDO1 [37]. It is tempting to specu-
late that the strong induction of an autocrine IFN-b loop by 
TLR ligation in hMSC [19] that is shared by plasmacytoid DC 
[38] is the critical determinant of the discrepancy between 
mMSC and hMSC.
Since these results did not rule out that IDO1 could be in-
duced by other signals delivered through interacting T cells 
or myeloid cells, we tested whether inhibition of IDO1 would 
lead to an incapacitation of mMSC to suppress the activation 
of myelin-specifi c T cells. Treatment with the competitive 
IDO1 inhibitor 1-l-MT did not rescue the immunosuppres-
sive phenotype in this setting (Fig. 5B). Interestingly, in the 
absence of mMSCs 1-l-MT suppressed T-cell proliferation 
not only indicating that IDO1-mediated trp catabolism does 
not restrict T-cell proliferation in this system but also sug-
gesting that 1-l-MT may have off-target effects. It has been 
reported that 1-l-MT modulates the function of APC inde-
pendently of IDO1 inhibition [39]. To more specifi cally delin-
eate the role of IDO1 in immunosuppression of mMSC, we 
generated MSC from bone marrow cells of IDO1-defi cient 
mice. IDO1-/- MSC were phenotypically similar to wild-type 
MSC with respect to surface marker expression, differenti-
ation, expression of TLR, and IL-6 induction (Fig. 6A–6D). 
IDO1 defi ciency in mMSC neither reversed mMSC-mediated 
suppression of antigen-specifi c T-cell proliferation in vitro 
(Fig. 6E) nor did it alter the therapeutic effects of mMSC in a 
mouse model of MS (Fig. 7A). Interestingly, both wild-type 
and IDO1-/- MSC led to a reduction of IL-17 production in 
myelin-specifi c CD4+ T cells ex vivo while IFN-g and TNF 
release was even more suppressed by IDO-defi cient mMSC 
(Fig. 7C). Rafei and colleagues have recently demonstrated a 
suppression of both TH1 and TH17 immunity by MSC [9,40]. 
The indistinguishable clinical outcome and the lack of dif-
ferences in TH cell proliferation between the 2 groups may 
indicate that mMSC are responsible for TH17 suppression 
rather than TH1 polarization of myelin-specifi c T cells in 
vivo. TH17 cells have shown to be critically involved in the 
pathogenesis of EAE, although their ultimate importance in 
EAE and in other models of autoimmune diseases remains 
controversial [41].
Conclusion
We show that IDO1 is dispensable for the immunosup-
pressive signals delivered by mMSC and for the therapeutic 
effects of autologous mMSC in autoimmune neuroinfl am-
mation. This is in sharp contrast to human MSC where IDO1 
is critically involved in the suppression of T-cell immunity 
[16,19]. The preclinical development of MSC as a cell-based 
therapy for autoimmune diseases in mouse models using 
autologous bone marrow-derived MSC should therefore 
be interpreted with caution with respect to its prediction 
for the therapeutic effi cacy of hMSC in human autoim-
mune diseases. Using hMSC in mouse models, which can 
effectively be done without obvious evidence of immune 
rejection [42], may be more appropriate for preclinical tri-
als characterizing and optimizing route of administration, 
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motility, cellular targets, and immunosuppressive mecha-
nisms of MSC in disease settings.
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